Clin Osteol 2004; 9(2): 54-58

The significance of subchondral bone in the pathogenesis of osteoarthritisArticles

L. Šenolt, K. Pavelka

In this paper the authors summarise the role of subchondral bone in the destruction of articular cartilage and initiation or progression of osteoarthri­ tis. Osteoarthritis is characterised by progressive articular cartilage loss and new bone formation, sclerosis of subchondral bone and osteophytes, on the other hand. Subchondral bone stiffness play probably not such an important role in the mechanism of cartilage deterioration as proposed earlier. In the light of new data, bone microcraks, neovascularization and osteoblasts produced eicosanoids, cytokines, proteolytic enzymes and growth factors could contribute to the abnormal cartilage metabolism and osteoarthritis pathogenesis. Some of the bone markers could also be predictive of ra­ diological progression of the disease. Moreover, it could highlight the importance of subchondral bone in the pathogenesis of osteoarthritis.

Keywords: subchondral bone, osteoarthritis, microcraks, neovascularization, eicosanoids, cytokines, proteolytic enzymes and growth factors.

Published: December 11, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šenolt L, Pavelka K. The significance of subchondral bone in the pathogenesis of osteoarthritis. Osteologický bulletin. 2004;9(2):54-58.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lawrence RC, Helmick GG, Arnett DF, et al. Estimates of the prevalence of arth­ ritis and selected musculosceletal disorders in the United States. Arthritis Rheum 1998;41:778-788. Go to original source...
    2. Brandt KD. Pathology. In: Brandt KD. Diagnosis and Nonsurgical Management of Osteoarthritis 2000;45-51.
    3. Aigner T, Zien A, Hanisch D, Zimmer R. Gene expression in chondrocytes asses­ sed with use of microarrays. J Bone Joint Surg Am. 2003; 85-A Suppl 2:117-23. Go to original source...
    4. Aigner T, Kurz B, Fukui N, Sandell L. Roles of chondrocytes in the pathogenesis of osteoarthritis. Curr Opin Rheumatol 2002;14:578-84. Go to original source...
    5. Westacott CI, Webb GR, Warnock MG, et al. Alteration of cartilage metabolism by cells from osteoarthritic bone. Arthritis Rheum. 1997;40:1282-91. Go to original source...
    6. Burr DB. The importance of subchondral bone in osteoarthrosis. Curr Opin Rheu­ matol 1998;10:256-62. Go to original source...
    7. Lajeunesse D, Reboul P. Subchondral bone in osteoarthritis: a biologic link with articular cartilage leading to abnormal remodeling. Curr Opin Rheumatol 2003;15:628-33. Go to original source...
    8. Dequeker J. Inverse relationship of interface between osteoporosis and osteoarth­ ritis. J Rheumatol 1997;24:795-8.
    9. Li B, Aspden RM. Mechanical and material properties of the subchondral bone plate from the femoral head of patients with osteoarthritis or osteoporosis. Ann Rheum Dis 1997;56:247-54. Go to original source...
    10. Cheng XG, Nicholson PH, Lowet G, et al. Prevalence of trabecular microcallus formation in the vertebral body and the femoral neck. Calcif Tissue Int 1997;60:479-84. Go to original source...
    11. Radin EL, Paul IL, Rose RM. Role of mechanical factors in pathogenesis of pri­ mary osteoarthritis. Lancet 1972;1:519-22. Go to original source...
    12. Radin EL, Abernethy PJ, Townsend PM, Rose RM. The role of bone changes in the degeneration of articular cartilage in osteoarthrosis. Acta Orthop Belg 1978;44:55-63.
    13. Radin EL, Parker HG, Pugh JW, et al. Response ofjoints to impact loading. 3. Re­ lationship between trabecular microfractures and cartilage degeneration. J Biomech 1973;6:51-7. Go to original source...
    14. Radin EL, Rose RM. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop 1986;213:34-40. Go to original source...
    15. Casden AM, Jaffe FF, Kastenbaum DM, Bonar SF. Osteoarthritis associated with osteopetrosis treated by total knee arthroplasty. Report of a case. Clin Orthop 1989;247:202-7. Go to original source...
    16. Dequeker J, Aerssens J, Luyten FP. Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. Aging Clin Exp Res 2003;15:426-39. Go to original source...
    17. Burr DB, Radin EL. Microfractures and microcracks in subchondral bone: are they relevant to osteoarthrosis? Rheum Dis Clin North Am 2003;29:675-85. Go to original source...
    18. Sokoloff L. Microcracks in the calcified layer of articular cartilage. Arch Pathol Lab Med 1993;117:191-5.
    19. Havelka&Horn. Observations on tidemark and calcified layer of articular caritlage, in: Archer and al, eds. Biology of the synovial joint. Amsterdam, Harwood Academic Publischers 1999:331-346.
    20. Laufer S. Role of eicosanoids in structural degradation in osteoarthritis. Curr Opin Rheumatol 2003;15:623-7. Go to original source...
    21. Wittenberg RH, Willburger RE, Kleemeyer KS, Peskar BA In vitro release of pro­ staglandins and leukotrienes from synovial tissue, cartilage, and bone in degene­ rative joint diseases. Arthritis Rheum 1993;36:1444-50. Go to original source...
    22. Massicotte F, Lajeunesse D, Benderdour M, et al. Can altered production of interleukin-1beta, interleukin-6, transforming growth factor-beta and prostaglandin E(2) by isolated human subchondral osteoblasts identify two subgroups of osteo­ arthritic patients. Osteoarthritis Cartilage 2002;10: 491-500. Go to original source...
    23. Paredes Y, Massicotte F, Pelletier JP, et al. Study of the role of leukotriene B 4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyc­ looxygenase and/or 5-lipoxygenase inhibition. Arthritis Rheum 2002;46:1804-12. Go to original source...
    24. J^velka K, Bias P, Buchner A et al. Licofelone, a 5-lipoxygenase, cyclooxygena­ se-1 and -2 inhibitor, is as effective as celecoxib and shows improved tolerability in osteoarthritis of the knee. Osteoarthritis Cart 2003;11,supp.A,110:40.
    25. Lajeunesse D, Martel-Pelletier J, Fernandes JC et al. Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteo­ arthritis. Ann Rheum Dis 2004;63:78-83. Go to original source...
    26. Hedbom E, Hauselmann HJ. Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Mol Life Sci 2002;59:45-53. Go to original source...
    27. Hilal G, Martel-Pelletier J, Pelletier JP, et al. Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: pos­ sible role in subchondral bone sclerosis. Arthritis Rheum 1998;41:891-9. Go to original source...
    28. Dore S, Pelletier JP, DiBattista JA, et al. Human osteoarthritic chondrocytes pos­ sess an increased number of insulin-like growth factor 1 binding sites but are un­ responsive to its stimulation. Possible role of IGF-1-binding proteins. Arthritis Rheum 1994;37:253-63. Go to original source...
    29. Dore S, Abribat T, Rousseau N, et al. Increased insulin-like growth factor 1 pro­ duction by human osteoarthritic chondrocytes is not dependent on growth hormo­ ne action. Arthritis Rheum 1995;38:413-9. Go to original source...
    30. Massicotte F, Lajeunesse D, Benderdour M, et al. Can altered production of interleukin-1beta, interleukin-6, transforming growth factor-beta and prostaglandin E(2) by isolated human subchondral osteoblasts identify two subgroups of osteo­ arthritic patients. Osteoarthritis Cartilage 2002;10:491-500. Go to original source...
    31. Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduction of os­ teophyte formation and synovial thickening by adenoviral overexpression of trans­ forming growth factor beta/bone morphogenetic protein inhibitors during experi­ mental osteoarthritis. Arthritis Rheum 2003;48:3442-51. Go to original source...
    32. Udagawa N, Kotake S, Kamatani N, et al. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4:281-9. Go to original source...
    33. Fazzalari NL, Kuliwaba JS, Atkins GJ, et al. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteo­ arthritis. J Bone Miner Res 2001;16:1015-27. Go to original source...
    34. Komuro H, Olee T, Kuhn K, et al. The osteoprotegerin/receptor activator of nuc­ lear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum. 2001;44:2768-76. Go to original source...
    35. Takemura M, Harada A, Mizuno M et al. Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disea­ se severity in individuals with osteoarthritis of the knee. Metabolism 2001;50:1-2. Go to original source...
    36. Chagraoui H, Tulliez M, Smayra T et al. Stimulation of osteoprotegerin produc­ tion is responsible for osteosclerosis in mice overexpressing TPO. Blood. 2003;101:2983-9. Go to original source...
    37. Guevremont M, Martel-Pelletier J, Massicotte F, et al. Human adult chondrocytes express hepatocyte growth factor (HGF) isoforms but not HgF: potential implica­ tion of osteoblasts on the presence of HGF in cartilage. J Bone Miner Res 2003;18:1073-81. Go to original source...
    38. Westacott CI, Webb GR, Warnock MG, et al. Alteration of cartilage metabolism by cells from osteoarthritic bone. Arthritis Rheum 1997;40:1282-91. Go to original source...
    39. Garnero P, Delmas PD. Biomarkers in osteoarthritis. Curr Opin Rheumatol 2003;15:641-6. Go to original source...
    40. Garnero P, Piperno M, Gineyts E, et al. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60:545-8. Go to original source...
    41. Bettica P, Cline G, Hart DJ, et al. Evidence for increased bone resorption in pati­ ents with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002;46:3178-84. Go to original source...
    42. Rovetta G, Monteforte P, Grignolo MC, et al. Hematic levels of type I collagen C-telopeptide in erosive versus nonerosive osteoarthritis of the hands. Int J Tissue React 2003;25:25-8.
    43. Garnero P, Landewe R, Boers M, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847-56. Go to original source...
    44. Kawabata TT. The potential of NE-58098, NE-10216, and EHDP to alter or pre­ vent osteoarthritis (osteoarthrosis) in the Hartley guinea pig. Project number 995.80.00-BL. Final Report 1996, Accession No.45317.
    45. Lehmann HJ, Mouritzen U, Christgau S, et al. Effect of bisphosphonates on carti­ lage turnover assessed with a newly developed assay for collagen type II degrada­ tion products. Ann Rheum Dis 2002;61:530-3. Go to original source...
    46. Otterness IG, Swindell AC, Zimmerer RO, et al. An analysis of 14 molecular mar­ kers for monitoring osteoarthritis: segregation of the markers into clusters and di­ stinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 2000;8:180-5. Go to original source...
    47. Otterness IG, Weiner E, Swindell AC, et al. An analysis of 14 molecular markers for monitoring osteoarthritis. Relationship of the markers to clinical end-points. Osteoarthritis Cartilage 2001;9:224-31. Go to original source...
    48. Bruyere O, Collette JH, Ethgen O, et al. Biochemical markers of bone and carti­ lage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol 2003;30:1043-50.
    49. Bruyere O, Collette JH, Ethgen O, et al. Biochemical markers of bone and carti­ lage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol 2003;30:910-2.
    50. Šenolt L, Braun M, Pavelka K. Konečné produkty pokročilé glykace u pacientů s osteoartrózou a revmatoidní artritidou a jejich potenciální úloha v patogenezi těchto onemocnění. Čes Revmatol 2003;3:146-56.
    51. Verzijl N, Bank RA, TeKoppele JM, DeGroot J. AGEing and osteoarthritis: a dif­ ferent perspective. Curr Opin Rheumatol 2003;15:616-22. Go to original source...
    52. Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone 2002;31:1-7. Go to original source...
    53. Paul RG, Bailey AJ. The effect of advanced glycation end-product formation upon cell-matrix interactions. Int J Biochem Cell Biol 1999;31:653-60. Go to original source...
    54. Takagi M, Kasayama S, Yamamoto T, et al. Advanced glycation endproducts sti­ mulate interleukin-6 production by human bone-derived cells. J Bone Miner Res 1997;12:439-46. Go to original source...
    55. Newberry WN, Zukosky DK, Haut RC. Subfracture insult to a knee joint causes alterations in the bone and in the functional stiffness of overlying cartilage. J Orthop Res 1997;15:450-5. Go to original source...
    56. Huebner JL, Hanes MA, Beekman B, et al. A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of na­ turally occurring osteoarthritis. Osteoarthritis Cartilage 2002; 10:758-67. Go to original source...
    57. Gannon FH, Sokoloff L. Histomorphometry of the aging human patella: histolo­ gic criteria and controls. Osteoarthritis Cartilage 1999;7:173-81. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.